

# Fiscal Year 2009 Annual Review of Glumetza® and Fortamet®

Oklahoma Health Care Authority

April 2010


## Current Prior Authorization criteria for Glumetza® and Fortamet®

Approval will be based on clinical documentation of inability to take other forms of generic metformin ER - after slow titration of 500 mg ER at 2 week intervals up to 2000 mg daily.

## Trends in Utilization of Glumetza® and Fortamet®

Fiscal Year	Members	Claims	Cost	Cost/ Claim	Per-Diem	Units	Days
2008	5	25	\$2,858.84	\$114.35	\$3.16	1,230	905
2009	6	27	\$4,569.24	\$169.23	\$4.62	1,560	990
% Change	20.0%	8.0%	59.8%	48.0%	46.2%	26.8%	9.4%
Change	1	2	\$1,710.40	\$54.88	\$1.46	330	85

## Member Demographics for Fiscal Year 2009



## Utilization Details of All Metformin Products for Fiscal Year 2009

Product	Claims	Members	Cost	Units/Day	Claims/Member	Cost/Day	Percent Cost
METFORMIN TAB 500MG	17,874	4,631	\$183,945.87	2.21	3.86	\$0.32	50.83%
METFORMIN TAB 1000MG	10,549	2,445	\$112,662.90	1.96	4.31	\$0.33	31.13%
METFORMIN TAB 500MG ER	2,094	561	\$27,195.26	2.24	3.73	\$0.39	7.52%
METFORMIN TAB 850MG	1,759	420	\$22,932.49	2.16	4.19	\$0.40	6.34%
METFORMIN TAB 750MG ER	208	56	\$2,788.42	1.44	3.71	\$0.38	0.77%
RIOMET SOL	48	14	\$3,748.01	14.82	3.43	\$2.65	1.04%
GLUCOPHAGE TAB 1000MG	13	1	\$2,417.99	2.96	13	\$6.20	0.67%
GLUCOPHAGE TAB XR 500MG	11	1	\$1,409.62	4.00	11	\$4.27	0.39%
GLUMETZA TAB 1000MG	10	1	\$2,038.80	2.00	10	\$6.80	0.56%
GLUMETZA TAB 500MG	9	3	\$769.17	2.00	3	\$2.85	0.21%
FORTAMET TAB 1000MG	8	2	\$1,761.27	1.00	4	\$4.19	0.49%
GLUCOPHAGE TAB 500MG	2	1	\$202.51	2.00	2	\$2.03	0.06%
	<b>32,585</b>	<b>7,283*</b>	<b>\$361,872.31</b>	<b>2.14</b>	<b>4.47</b>	<b>\$0.34</b>	<b>100.00%</b>

\*Total number of unduplicated members


## Prescribers of Metformin Extended Release Products: FY 2009

Specialty	Claims	Total Paid
General Pediatrician	15	\$2,457.65
DDSD-NFM	6	\$1,484.37
Physician Assistant	3	\$262.74
Nurse Practitioner (Other)	2	\$276.90
General Practitioner	1	\$87.58

## Prior Authorization of Metformin Extended Release Products: FY 2009

The total number of petitions for this category was 15. The following are the status of the submitted petitions.

■ Approved ■ Denied ■ Incomplete



## Recommendations

The College of Pharmacy does not recommend any changes to the Glumetza® and Fortamet® Prior Authorization Criteria at this time.